Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Sign Informed Consent document.~* Diagnosis of open-angle glaucoma or ocular hypertension, with mean intraocular pressure within protocol-specified range at eligibility visit/s.~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Females of childbearing potential if pregnant, lactating, or not using highly effective birth control measures.~* Any form of glaucoma other than open-angle glaucoma.~* Severe central vision loss in either eye.~* Chronic, recurrent, or severe inflammatory eye disease.~* Ocular trauma within the preceding 6 months.~* Ocular infection or ocular inflammation within the preceding 3 months.~* Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment.~* Best-corrected visual acuity score worse than 55 letters using the Early Treatment Diabetic Retinopathy Study chart.~* Other ocular pathology (including severe dry eye) that may, in the opinion of the Investigator, preclude the administration of study product.~* Ocular surgery within the preceding 6 months.~* Ocular laser surgery within the preceding 3 months.~* Any abnormality preventing reliable applanation tonometry.~* Any other conditions, including severe illness, which could make the patient, in the opinion of the Investigator, unsuitable for the study.~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brinzolamide/Brimonidine (Type: EXPERIMENTAL): Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
- Brinzolamide (Type: ACTIVE_COMPARATOR): Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
- Brimonidine (Type: ACTIVE_COMPARATOR): Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).